Compass Therapeutics Sees Unusually Large Options Volume (NASDAQ:CMPX)

Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) was the target of some unusual options trading on Tuesday. Traders bought 22,702 put options on the company. This represents an increase of 797% compared to the typical volume of 2,532 put options.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in CMPX. Squarepoint Ops LLC acquired a new position in shares of Compass Therapeutics in the 4th quarter valued at $35,000. Tang Capital Management LLC lifted its position in Compass Therapeutics by 225.4% in the fourth quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company's stock valued at $8,555,000 after buying an additional 4,087,005 shares during the last quarter. ProShare Advisors LLC boosted its position in shares of Compass Therapeutics by 49.0% during the 4th quarter. ProShare Advisors LLC now owns 28,722 shares of the company's stock worth $42,000 after purchasing an additional 9,451 shares during the period. MPM Bioimpact LLC boosted its position in shares of Compass Therapeutics by 51.9% during the fourth quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company's stock worth $12,423,000 after buying an additional 2,926,002 shares during the period. Finally, Enavate Sciences GP LLC purchased a new position in Compass Therapeutics during the 4th quarter valued at about $11,293,000. 68.43% of the stock is currently owned by hedge funds and other institutional investors.

Compass Therapeutics Stock Performance

Shares of CMPX stock traded down $0.09 during trading hours on Thursday, reaching $1.61. The company had a trading volume of 1,908,897 shares, compared to its average volume of 808,707. The stock has a fifty day moving average of $2.78 and a 200-day moving average of $2.10. The company has a market capitalization of $221.94 million, a price-to-earnings ratio of -4.34 and a beta of 1.19. Compass Therapeutics has a 12-month low of $0.77 and a 12-month high of $4.08.

Remove Ads

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). On average, analysts forecast that Compass Therapeutics will post -0.36 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on CMPX shares. Jefferies Financial Group increased their target price on Compass Therapeutics from $7.00 to $8.00 and gave the company a "buy" rating in a research report on Monday, February 10th. Leerink Partners upgraded shares of Compass Therapeutics from a "market perform" rating to an "outperform" rating and lifted their target price for the company from $4.00 to $6.00 in a research report on Wednesday. D. Boral Capital restated a "buy" rating and set a $32.00 price target on shares of Compass Therapeutics in a research report on Tuesday. Wedbush reiterated an "outperform" rating and issued a $8.00 price objective on shares of Compass Therapeutics in a report on Tuesday. Finally, Guggenheim reiterated a "buy" rating and set a $12.00 price objective on shares of Compass Therapeutics in a research note on Wednesday. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $11.63.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.